Scroll To Top
Health

Trial run can predict who will adhere to HIV antiretrovirals

Trial run can predict who will adhere to HIV antiretrovirals

We need your help
Your support makes The Advocate's original LGBTQ+ reporting possible. Become a member today to help us continue this work.

Participating in a two-week trial with mock medications before starting an actual anti-HIV drug regimen can predict how well a person will adhere to the regimen, with people who best followed dosing instructions ultimately having the best chances of achieving undetectable blood-based HIV viral loads, aidsmap.com reports. The study, conducted at two hospitals in South Carolina, showed that 75% of patients who were able to take 90% of their mock medications as directed during the two-week trial were able to achieve undetectable viral loads when given real anti-HIV drugs. Only about half of those who took less than 90% of their mock drugs on time had undetectable HIV viral loads on highly active antiretroviral therapy.

Pride of Broadway Special

From our Sponsors

Most Popular

Latest Stories

Advocate.com Editors